Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 9/20 | 0.55 |
| ▸ | FNTB | P49356 | 9/20 | 0.55 |
| ▸ | SLC6A15 | Q9H2J7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13604329 | 0.85 | FNTA (0.39) | FNTAFNTBSLC6A15 | |
| SCHEMBL13611706 | 0.82 | FNTA (0.58) | FNTAFNTBSLC6A15 | |
| SCHEMBL1978262 | 0.80 | FNTA (0.60) | FNTAFNTB | |
| SCHEMBL13604328 | 0.79 | FNTA (0.50) | FNTAFNTB | |
| SCHEMBL14289895 | 0.79 | FNTA (0.58) | FNTAFNTBSLC6A15 | |
| SCHEMBL6176740 | 0.79 | FNTA (0.58) | FNTAFNTB | |
| SCHEMBL14288461 | 0.74 | MEN1 (0.56) | FNTAFNTBSLC6A15 | |
| SCHEMBL9827245 | 0.74 | SRD5A1 (0.46) | — | |
| SCHEMBL14102189 | 0.74 | MEN1 (0.58) | FNTAFNTB | |
| SCHEMBL14102072 | 0.74 | MEN1 (0.58) | FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210155634-A1 | NOVEL TRYPTOPHAN HYDROXYLASE INHIBITOR AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2021-05-27 | — | — | US | disclosed |
| US-7635697-B2 | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases | SCHERING CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635697-B2 | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases | SCHERING CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155634-A1 | NOVEL TRYPTOPHAN HYDROXYLASE INHIBITOR AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | TPH1, TPH2, IDO1 | FNTA 3630/4885FNTB 4169/4885SLC6A15 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.